As clinical trials of potential coronavirus vaccines continue, the UK government has drawn up a list of those who should be first in line for vaccination, although it cautions that many unknowns remain in areas such as efficacy, dosing schedules and duration of protection.

Hanmi is reviewing a new global clinical trial plan for its novel lung cancer drug olmutinib after China's ZAI Lab returned its rights, and following Boehringer’s cancellation of a major-licensing deal in 2016. ZAI's decision may reflect the difficulties faced by olmutinib and other third generation EGFR inhibitors in competing with Tagrisso, as well as the increasingly crowded and rapidly changing non-small cell lung cancer space.

Improving gender balance in top pharma is a slow process, but not a gradual one. Management shake-ups often implemented by newly appointed CEOs could help.

Price gains and a regulator that has turned more responsive appear to be among the key factors contributing to the improving sentiment in Brazil for India's Torrent even as the South American nation tackles intense political and economic turbulence. While Torrent reported a sharp decline in its earnings in the first quarter largely due to exceptional gains in the comparable previous period, its Brazilian business is looking up.